AstraZeneca PE Ratio 2006-2018 | AZN

Current and historical p/e ratio for AstraZeneca (AZN) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AstraZeneca PE ratio as of April 17, 2019 is 11.20.
AstraZeneca PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-04-18 38.80 22.82
2018-12-31 37.98 $1.70 22.34
2018-09-30 39.57 $1.91 20.72
2018-06-30 34.72 $2.11 16.45
2018-03-31 34.58 $2.22 15.58
2017-12-31 33.38 $2.37 14.08
2017-09-30 32.59 $2.79 11.68
2017-06-30 32.30 $3.05 10.59
2017-03-31 29.50 $2.67 11.05
2016-12-31 25.06 $2.76 9.08
2016-09-30 30.14 $1.95 15.46
2016-06-30 27.32 $1.76 15.53
2016-03-31 25.49 $2.31 11.03
2015-12-31 29.79 $2.02 14.75
2015-09-30 27.92 $1.26 22.25
2015-06-30 27.58 $0.75 37.02
2015-03-31 29.62 $0.51 58.08
2014-12-31 29.63 $0.49 60.47
2014-09-30 30.08 $0.41 74.26
2014-06-30 30.88 $0.80 38.60
2014-03-31 26.96 $0.82 33.08
2013-12-31 23.98 $1.02 23.51
2013-09-30 20.97 $1.84 11.40
2013-06-30 18.77 $1.95 9.62
2013-03-31 19.83 $2.26 8.79
2012-12-31 18.01 $2.49 7.23
2012-09-30 18.23 $2.46 7.41
2012-06-30 16.73 $3.14 5.34
2012-03-31 16.63 $3.26 5.10
2011-12-31 16.59 $3.66 4.54
2011-09-30 15.90 $3.65 4.36
2011-06-30 17.61 $2.90 6.07
2011-03-31 16.22 $2.87 5.66
2010-12-31 15.64 $2.79 5.61
2010-09-30 17.16 $2.75 6.24
2010-06-30 15.74 $2.95 5.34
2010-03-31 14.93 $2.81 5.31
2009-12-31 15.10 $2.60 5.82
2009-09-30 14.46 $2.49 5.81
2009-06-30 14.02 $2.36 5.95
2009-03-31 11.26 $2.32 4.85
2008-12-31 12.54 $2.10 5.98
2008-09-30 13.41 $2.10 6.40
2008-06-30 12.85 $1.96 6.57
2008-03-31 11.48 $1.88 6.12
2007-12-31 12.50 $1.87 6.69
2007-09-30 14.62 $1.91 7.67
2007-06-30 15.46 $1.96 7.91
2007-03-31 15.51 $1.99 7.81
2006-12-31 15.16 $1.93 7.87
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $98.200B $22.090B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $371.636B 16.85
Pfizer (PFE) United States $237.400B 13.29
Merck (MRK) United States $199.302B 17.03
Novartis AG (NVS) Switzerland $178.563B 15.19
Eli Lilly (LLY) United States $120.673B 20.95
Novo Nordisk (NVO) Denmark $118.536B 19.17
AbbVie (ABBV) United States $115.027B 9.86
Sanofi (SNY) France $103.057B 12.72
GlaxoSmithKline (GSK) United Kingdom $99.174B 13.02
Bristol-Myers Squibb (BMY) United States $74.835B 11.51